Navigation Links
Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
Date:12/3/2008

SOUTH SAN FRANCISCO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that members of Rigel's senior management team will host a conference call with simultaneous webcast on Sunday, December 7, 2008, at 4:00 p.m. PST, to discuss the results of Rigel's Phase 2 clinical trial of R788, an oral Syk kinase inhibitor, in patients with B-cell non-Hodgkin's lymphomas.

Conference Call and Webcast Information

To access the live call, please dial 800-561-2693 (domestic) or 617-614-3523 (international) 10 minutes prior to the start time and use the passcode 36883961. A replay of the call will be available, in webcast and podcast formats, at approximately 6:00 p.m. PST on December 7, 2008 through December 14, 2008. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and use the passcode 47095093. The conference call will also be webcast live and can be accessed from Rigel's website at http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.

In addition, Rigel will be participating in a plenary session during the 50th Annual American Society of Hematology (ASH) Meeting in San Francisco, California from December 6-9, 2008.

ASH Presentation Details

Plenary session: Sunday, December 7, 2008 - 2:40 p.m. PST

Title: 3 - Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B-Cell Lymphoma (DLBCL) and Chronic Lymphoctytic Leukemia (SLL/CLL)

Location: Halls B and C (Moscone Center)

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

     Contact: Raul Rodriguez
     Phone: 650.624.1302
     Email: invrel@rigel.com

     Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
     Phone: 650.430.3777
     Email: susan@alchemyemail.com

'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Rigel to Present at the 2008 Credit Suisse Healthcare Conference
2. Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
3. Rigel to Host Update Conference Call
4. Rigel Announces Fourth Quarter and Year End 2007 Financial Results
5. Rigel to Present at BIO CEO & Investor Conference
6. Rigel Announces Pricing of Public Offering of Common Stock
7. Rigel to Present Research Programs at Scientific Conferences
8. Rigel to Present at BIO Investor Forum 2007
9. Abaxis, Inc. to Present at the RBC Capital Markets 2008 Healthcare Conference
10. Medarex to Present at the RBC Capital Markets Healthcare Conference
11. Bionovo to Present at the Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... COPENHAGEN, Denmark , March 22, 2017 /PRNewswire/ ... that utilizes its innovative TransCon technology to address ... announced financial results for the full year ended ... a significant year for our company as we ... become a leading, integrated rare disease company with ...
(Date:3/22/2017)... March 22, 2017 Oramed Pharmaceuticals Inc. ... www.oramed.com ), a clinical-stage pharmaceutical ... delivery systems, announced today that Dr. Miriam ... a presentation titled, "Oral Insulin for Diabetes Treatment: ... Healthtech Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... -- MarketNewsUpdates.com News Commentary  ... The traditional ways to treat ... of late due to the rise of the opioid crisis. ... impact on patient,s quality of life as Biotech and Pharma ... forms of opioid formulations that prevent abuse. Biotech and Pharma ...
(Date:3/22/2017)... RADNOR, Pa. , March 22, 2017 ... leading global independent provider of product and ... announced today that it has acquired EPL ... that supports customers across the entire regulated ... providing archive sample, document storage and ancillary ...
Breaking Biology Technology:
(Date:3/22/2017)... Optimove , provider of the ... as 1-800-Flowers and AdoreMe, today announced two new ... Using Optimove,s machine learning algorithms, these features allow ... recommendations to their customers based not just on ... intent drawn from a complex web of data ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... Matching enables to match face pictures against each other or against large databases. ... Systems) ... the fastest software for biometric Face Matching on the market. The speed is ...
(Date:3/6/2017)... March 6, 2017 Mintigo , ... today announced Predictive Sales Coach TM , its ... sales intelligence into Salesforce. This unique AI application ... sales organizations with deep knowledge of their customers ... intelligent engagement. Predictive Sales Coach extends Mintigo,s existing ...
Breaking Biology News(10 mins):